Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Kelly Garrity

Kelly Garrity

Northwell Health, USA

Title: Butorphanol use in laboring patients with preeclampsia or chronic hypertension

Biography

Biography: Kelly Garrity

Abstract

The American College of Obstetricians and Gynecologists (ACOG) recommends against the use of butorphanol in patients diagnosed with preeclampsia or chronic hypertension secondary to a theoretical concern that the drug will further elevate blood pressures. No study has examined the drug’s potential to elevate blood pressures in laboring patients. In this retrospective cohort study, all chronic hypertensive and preeclamptic patients who underwent an induction of labor and delivered a viable, singleton pregnancy between the dates of 1/1/2013-12/31/2014 at a Single Academic Hospital were included. The use of butorphanol in chronically hypertensive patients during labor was not associated with the presence of severe range blood pressures during labor [OR=0.92, 95% CI: (0.04-19.34) P=0.96]. In preeclamptic patients, there was similarly no change in the frequency of severe range blood pressures with the use of the drug [OR=0.59, 95% CI: (0.19-1.83) P=0.36]. In laboring patients with chronic hypertension or preeclampsia, butorphanol is not associated with severe range blood pressures and therefore it is a reasonable option for providing pain relief in these populations.